Indonesia and Morocco Pharmaceuticals and Healthcare Industry Report Q4 2012

Indonesia Pharmaceuticals and Healthcare Report Q4 2012

The potential of Indonesia’s pharmaceutical market will be boosted by the authorities’ aim to provide universal health coverage from the start of 2014. However, the Indonesian government must ensure that it calculates its financial ability to run the national healthcare programme, or risk the programme failing according to Hotbonar Sinaga of the University of Indonesia and Bambang Purwoko of the Pancasila University, cited by the Jakarta Post. In the meantime, innovative drugmakers will continue to face legislative and market access barriers in the country, although improvements are expected in the coming years, partly due to outside insistence on the country’s compliance with international intellectual property (IP) and similar standards.

Report Details:

Published: Oct 2012

Price: Single User License: US $1175

 

                                           

 

Indonesia Pharmaceuticals Market Headline Expenditure Projections:

- Pharmaceuticals: IDR53,041bn (US$6.04bn) in 2011 to IDR58,706bn (US$6.33bn) in 2012; +10.7% growth in local currency terms and +4.7% in US dollar terms. Local currency forecast unchanged from previous quarter.

- Healthcare: IDR195,355bn (US$22.26bn) in 2011 to IDR223,410bn (US$24.09bn) in 2012; +14.4% growth in local currency terms and +8.2% in US dollar terms. Local currency forecast unchanged from previous quarter.

- Medical devices: IDR5,721bn (US$652mn) in 2011 to IDR6,290bn (US$678mn) in 2012; +10.0% growth in local currency terms and +4.0% in US dollar terms. Local currency forecast unchanged from previous quarter.

Buy your copy of this report @ http://www.rnrmarketresearch.com/indonesia-pharmaceuticals-and-healthcare-report-q4-2012-market-report.html

Risk/Reward Rating: In our Q412 Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), Indonesia remains ranked 11th out of the 18 Asia Pacific markets. Its composite score – an unchanged 48.4 out of 100 – is composed of average rewards (53, slightly above the regional average of 51) and elevated risks (of 42, contrasting with the regional average of 57). Globally, Indonesia ranks 51st out of the 95 markets surveyed.

Morocco Pharmaceuticals and Healthcare Report Q4 2012

Morocco’s pharmaceutical market is medium-sized by regional standards and small on a global scale, but its high growth potential offers some attraction which its relatively low per capita drug consumption, especially in rural areas offsets. Morocco’s economy is going through a rough patch. Economic activity has been hit on several fronts, not least due to the export sector’s heavy exposure to the ongoing eurozone recession as well as a sharply lower agricultural harvest – the result of poor weather. Morocco’s recently introduced subsidised health insurance scheme, Régime d’Assistance Médicale (RAMED), may become increasingly difficult to finance. 

Report Details:

Published: Oct 2012

Price: Single User License: US $1175

 

                                           

Morocco Pharmaceuticals Headline Expenditure Projections

- Pharmaceuticals: MAD10.10bn (US$1.25bn) in 2011 to MAD11.16bn (US$1.30bn) in 2012; +10.5% in local currency terms and +3.8% in US dollar terms. Forecast broadly unchanged from Q312.

- Healthcare: MAD42.10bn (US$5.20bn) in 2011 to MAD46.9bn (US$5.44bn) in 2012; +11.3% in local currency terms and +4.6% in US dollar terms. Forecast broadly unchanged from Q312.

- Medical devices: MAD2.19bn (US$270mn) in 2011 to MAD2.45bn (US$285mn) in 2012; +12.3% in local currency terms and +5.5% in US dollar terms. Forecast broadly unchanged from Q312.

Buy your copy of this report @ http://www.rnrmarketresearch.com/morocco-pharmaceuticals-and-healthcare-report-q4-2012-market-report.html

Risk/Reward Rating: In Q412, Morocco remains 11th out of the 30 markets included in the MEA region, though its composite score remains unchanged. The country’s rewards ratings are less promising than its risks profile, which weighs on its overall score. The market is medium-sized by regional standards and small on a global scale, but its high growth potential offsets relatively low per capita drug consumption, especially in rural areas. In the risks category, Morocco scores above the regional average, indicating a relatively low level of country and pharmaceutical industry-specific risk in a relatively volatile region.